Effects of High Oleic Palm Olein, Virgin Olive Oil and Coconut Oil Diets on Markers Selected in Malaysian

Effects of High Oleic Palm Olein (HOPO), Virgin Olive Oil (OO) and Refined Bleached and Deodorized (RBD) Coconut Oil (CO) Diets on Lipid Profile, Markers of Insulin Resistance, Inflammatory and Obesity in Overweight Subject.

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02245113

Enrollment

Registered

2014-09-19

Start date

2013-12-31

Completion date

2014-07-31

Last updated

2014-09-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Overweight

Brief summary

This study will be comparing human body responses by the effects of diets cooked with NoveLin, virgin olive oil and RBD coconut oil.

Detailed description

NoveLin has high content of monounsaturate fatty acids - oleic acid (C18:1) which is the predominant fatty acid and in this study NoveLin is used as cooking fat in compare with olive oil. Olive oil is the world's most commonly eaten monounsaturated oil which contains 55 - 83% oleic acid. Consumption of olive oil gives numerous health benefits on lowering total and LDL cholesterol, reducing LDL cholesterol's, lowering blood clotting factors, and lowering blood pressure. Coconut oil is the richest source of medium chain fatty acid and it has greater than 90% of saturated fatty acid with dominant fatty acid of lauric acid (C12:0). RBD coconut oil is used as positive control in this study.

Interventions

OTHERdiets

Feeding trial for 6 weeks (week 0 - baseline). The experimental diets are comprised of 30% kcal fat, 15% kcal protein and 55% kcal carbohydrate. Each of the test fat contributes to two-thirds of total dietary fat will be compared.

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Masking

SINGLE (Subject)

Eligibility

Sex/Gender

ALL

Age

20 Years to 60 Years

Healthy volunteers

Yes

Inclusion criteria

* males and females aged 20-60 years * BMI 23 - 27.5 kg/m2 * free from any disease * not on any medication or treatment associated with reduction of CVD * non-smokers and non-heavy drinker or having smoking or alcoholic history * not pregnant or lactating * willing and able to comply

Exclusion criteria

* people on weight reduction therapy/program * people on cholesterol reduction medicatio * have one or more of the chronic diseases * people with blood clotting problem/ coagulopathy / deep vein thrombosis. * hypertensive persons (systolic pressure \> 140 mmHg, diastolic pressure \> 90 mmHg) * female who is pregnant * people travel to overseas during feeding.

Design outcomes

Primary

Measure	Time frame
change in c-peptide level	week 0(baseline) and week 6

Secondary

Measure	Time frame
change in insulin resistance's markers	week 0(baseline) and week 6
change in inflammatory markers	week 0(baseline) and week 6
change in obesity markers	week 0(baseline) and week 6
change in lipid profile	week 0(baseline) and week 6
change in physical characteristic (eg. BMI, body weight)	week 0(baseline) and week 6

Countries

Malaysia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026